Skip to main content
Enter your The Contraceptive Pipeline Database username.
Enter the password that accompanies your username.
Gestodene and EE Patch
FC-Patch low, Lisvy®
SRA/WHO PQ Approved
One patch applied once per week for three weeks (21 days) followed by one week without patch per cycle. Each patch contains 0.55 mg ethinyl estradiol (EE) and 2.1 mg gestodene.
May 30, 2018
Active Pharmaceutical Ingredient (API):
Potential Multi-Purpose Technology (MPT):
weekly (3 weeks on, 1 week without patch)
0.02mg EE and 0.05mg gestodene per day
Gedeon Richter Plc.
This patch was approved in the EU in 2014 and has been outlicensed by Bayer to Gedeon Richter, a Hungarian Pharma company. Market entry is planned for late 2015, with the name of Lisvy®.
Smallest size patch to date (11cm²). Only transparent contraceptive patch to date.
Small proportion of patches detach either partially or completely. Additional potential side effect is application site reaction.
Gedeon Richter Plc. website
Download Product Report